Terms: = Lung cancer AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Treatment
2722 results:
1. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
Dai Z; Xu J; Chang F; Zhou W; Ren T; Qiu J; Lu Y; Lu Y
Front Public Health; 2024; 12():1333487. PubMed ID: 38699428
[TBL] [Abstract] [Full Text] [Related]
2. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
Kong Y; Hong L; Xu XC; Chen YF; Xu J
PLoS One; 2024; 19(4):e0301931. PubMed ID: 38683829
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
4. Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer.
Grant C; Nagasaka M
Cancer Treat Rev; 2024 May; 126():102724. PubMed ID: 38636443
[TBL] [Abstract] [Full Text] [Related]
5. Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce lung cancer Regrowth after Crizotinib treatment.
Horvat NK; Chocarro S; Marques O; Bauer TA; Qiu R; Diaz-Jimenez A; Helm B; Chen Y; Sawall S; Sparla R; Su L; Klingmüller U; Barz M; Hentze MW; Sotillo R; Muckenthaler MU
ACS Nano; 2024 Apr; 18(17):11025-11041. PubMed ID: 38626916
[TBL] [Abstract] [Full Text] [Related]
6. Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with alk fusion: a case report and review of the literature.
Zhang P; Xu J; Wu Q; Qian J; Wang S
Diagn Pathol; 2024 Apr; 19(1):58. PubMed ID: 38616252
[TBL] [Abstract] [Full Text] [Related]
7. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker lung Adenocarcinoma Patients without EGFR or alk Alterations.
Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
[TBL] [Abstract] [Full Text] [Related]
8. Precision nanomedicine to treat non-small cell lung cancer.
Dessai A; Nayak UY; Nayak Y
Life Sci; 2024 Jun; 346():122614. PubMed ID: 38604287
[TBL] [Abstract] [Full Text] [Related]
9. [A case of crizotinib-associated renal cysts].
Quan LL; Huang P; Liang YC; Chen FW; Liu SB; Xin WW
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):356-359. PubMed ID: 38599812
[TBL] [Abstract] [Full Text] [Related]
10. Alectinib in Resected
Wu YL; Dziadziuszko R; Ahn JS; Barlesi F; Nishio M; Lee DH; Lee JS; Zhong W; Horinouchi H; Mao W; Hochmair M; de Marinis F; Migliorino MR; Bondarenko I; Lu S; Wang Q; Ochi Lohmann T; Xu T; Cardona A; Ruf T; Noe J; Solomon BJ;
N Engl J Med; 2024 Apr; 390(14):1265-1276. PubMed ID: 38598794
[TBL] [Abstract] [Full Text] [Related]
11. Anaplastic lymphoma kinase-positive pulmonary inflammatory myofibroblastic tumour: a case report.
Tong D; Chisholm J; Madden B; Ahmed M
J Med Case Rep; 2024 Apr; 18(1):167. PubMed ID: 38594735
[TBL] [Abstract] [Full Text] [Related]
12. New treatment Options for Patients With Oncogene-Addicted Non-Small Cell lung cancer Focusing on
Saw SPL; Le X; Hendriks LEL; Remon J
Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e432516. PubMed ID: 38560815
[TBL] [Abstract] [Full Text] [Related]
13. The prognostic value and model construction of inflammatory markers for patients with non-small cell lung cancer.
Xu W; Liu X; Yan C; Abdurahmane G; Lazibiek J; Zhang Y; Cao M
Sci Rep; 2024 Mar; 14(1):7568. PubMed ID: 38555313
[TBL] [Abstract] [Full Text] [Related]
14. Biomarker Turnaround Times and Impact on treatment Decisions in Patients with Advanced Non-Small Cell lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional cancer Centre.
Fleming KE; Hupel A; Mithoowani H; Lulic-Kuryllo T; Valdes M
Curr Oncol; 2024 Mar; 31(3):1515-1528. PubMed ID: 38534948
[No Abstract] [Full Text] [Related]
15. The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer.
Wallace ND; Alexander M; Xie J; Ball D; Hegi-Johnson F; Plumridge N; Siva S; Shaw M; Harden S; John T; Solomon B; Officer A; MacManus M
Lung Cancer; 2024 Apr; 190():107531. PubMed ID: 38513538
[TBL] [Abstract] [Full Text] [Related]
16. Genomic testing and targeted therapy of non-small cell lung cancer in China: a nationwide survey of physicians and clinical pathologists.
Wang J; Ying J; Wang Z; Meng X; Wu M; Qian C
Ann Palliat Med; 2024 Mar; 13(2):221-229. PubMed ID: 38509647
[TBL] [Abstract] [Full Text] [Related]
17. Clinical Management of Patients with Non-Small Cell lung cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.
Khasraw M; Yalamanchili P; Santhanagopal A; Wu C; Salas M; Meng J; Karnoub M; Esker S; Felip E
Adv Ther; 2024 May; 41(5):1815-1842. PubMed ID: 38509433
[TBL] [Abstract] [Full Text] [Related]
18. [Chinese expert consensus on iruplinalkib for the treatment of locally advanced or metastatic alk-positive non-small cell lung cancer (2024 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):189-205. PubMed ID: 38494766
[TBL] [Abstract] [Full Text] [Related]
19. Survival benefit in EGFR-wild and alk negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.
Jung HA; Park B; Park S; Sun JM; Lee SH; Seok Ahn J; Ahn MJ
Lung Cancer; 2024 Apr; 190():107536. PubMed ID: 38493759
[TBL] [Abstract] [Full Text] [Related]
20. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of alk, ROS1, RET fusions and MET exon 14 skipping in NSCLC.
Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
[TBL] [Abstract] [Full Text] [Related]
[Next]
